Effects of MTRPs Therapy in Migraine. (MTRPs)

March 1, 2023 updated by: Maciej Olesiejuk, Józef Piłsudski University of Physical Education

Effects of Myofascial Trigger Points Therapy in Migraine.

Case series, repeated-measures design, pilot study.

Adult, female, migraine patients underwent seven Ischemic Compression Myofascial Trigger Points (IC-MTrPs) therapy sessions.

The aim of the study is to investigate whether therapy of the shoulder girdle and neck muscles by deactivating MTrPs causes modification of biomechanical and biochemical variables in the blood and reduces headache in people with migraine, improving their quality of life by improving their health.

People qualified for the study were divided into 3 groups according to the type of migraine:

  1. CM group - patients with chronic migraine
  2. EMa group - patients with paroxysmal migraine with aura
  3. EMb group - patients with paroxysmal migraine without an aura.

All patients underwent 7 interventions in the area of the muscles of the shoulder girdle and neck (by deactivating trigger points) performed every 2 or 3 days. They did not take any headache medications during the treatment period. However, during a migraine attack, they could undergo treatments and research measurements. Biomechanical measurements of the cervical spine, shoulder girdle muscles and blood chemistry were performed before, during and after the patients' therapy.

All treatments were performed on the following muscles:

  • m. trapesius pars descendent (trapezius upper),
  • m. sternocleidomastoideus (sternocleidomastoid),
  • m. temporalis (temporal),
  • m. legator scapulae (levator scapula),
  • m. supraspinatus (supraspinatus),
  • m. suboccipitales (suboccipital).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Detailed Description:

I. The specific objectives were to investigate whether the therapy of the shoulder girdle and neck had an effect on:

  1. the range of mobility of the cervical spine
  2. myometric variables (stiffness, flexibility and tension) of the muscle (trapezius upper part)
  3. concentration of selected biochemical factors (S100 beta protein, substance P (SP), calcitonin gene-related peptide (CGRP), brain-derived neurotrophic factor (BDNF) in patients with migraine
  4. feel headache
  5. feel pain in the muscles of the shoulder girdle
  6. feel the quality of life related to health.

II. Hypotheses

  1. Inactivation of MTrPs by IC-MTRPs therapy improves biomechanical properties of the cervical spine (increases the range of mobility of the cervical spine - lateral inclination, rotation and forward inclination) in people with migraine.
  2. Inactivation of MTrPs by IC-MTRPs therapy improves the resting biomechanical properties (reduction of tension, stiffness and increased flexibility) of the muscles of the shoulder girdle.
  3. Inactivation of MTrPs by IC-MTRPs therapy reduces the concentration of biochemicals in the blood responsible for the aggravation of migraine pain.
  4. TOBS therapy through IC-MTrPs therapy improves biomechanical and biochemical variables, reducing the sensations of headache and muscle pain, improving health-related quality of life in people with migraine.

III. The course of research. Before and during the intervention cycle, migraine patients were subjected to biomechanical and biochemical tests. In the morning, fasting blood was drawn on the first and last day of therapy, before and after the intervention, in order to determine the biochemical parameters. Before the start of therapy and one month after the last intervention, the patients completed the WHOQoL-BREF (WHO Quality of Life BREEF) and the VAS (visual analogue scale) for headache and muscle pain during therapy. Before and after the first, fourth and seventh interventions, and one month after the last treatment, myometric measurements of muscle tension, stiffness and flexibility were performed using the Myoton Pro 3 apparatus (Tallinn, Estonia), and biomechanical measurements of cervical spine mobility using the Myo Motion apparatus (Noraxon, Scottsdale, USA). Muscle pain and headache during the procedure were also assessed using the VAS scale.

The research was carried out during eight research sessions in the morning, which were carried out according to a strictly defined scheme (for all subjects in the same order and location)

IV. Research methods. IV (I) Anthropometric measurements. The subjects' height, weight and body composition were measured using the Tanita BC 418 ma electronic system (Tanita Corporation, Tokyo, Japan T174). Measurement of body mass composition was determined by the electrical bioimpedance (BIA) method. The obtained data were necessary to carry out myometric and accelerometric measurements (mobility of the cervical spine), where it was required to provide the current weight and height of the examined person.

IV (II) Biochemical determinations. Blood collection and serum collection. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am before and after the treatment on the first day and 24 hours after the sixth treatment, into test tubes without serum anticoagulants. The sterile blood (8 ml) was left for 30 min at room temperature, then the blood was centrifuged at 1500 rpm / min x g for 10 min. Serum was transferred to new 300 µl tubes and stored at -70 ° C until biochemical determinations were made.

Determination of the concentration of SP and S100B, CGRP, BNDF with the immunochemical method of ELISA The concentration of substance P, protein S100beta, calcitonin gene-related peptide (CGRP), BNDF (brain-derived neurotrophic factor) was determined using the immunochemical ELISA method in accordance with the instructions of the kit manufacturers (R&D systems, Londyn UK).

IV (III) Biomechanical measurements of the cervical spine Determination of biomechanical parameters of the cervical spine. For mobility measurements, a set for recording and analyzing human movement in 3D with the use of Noraxon Myo Motion accelerometric sensors (Noraxon, Scottsdale, USA) was used. The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. Automatic recording of motion parameters completely eliminated errors related to the subjective assessment of a diagnostician with the use of manual measuring tools. The ROM values will be expressed in degrees [°].

Sensors (sensor 1 was mounted at the height of the first spinous process of the thoracic spine (Th1), sensor 2 was mounted on the occiput (Co)) mounted on the patient's head, on an elastic band, have the function of automatic, wireless calibration, thanks to which the above-described data was collected before and after day 1, 4 and 7 of therapy for the muscles of the shoulder girdle and neck and for 1 month after the last intervention. Each of the examined women sat on a stiff armchair, fastened with belts preventing the movement of the torso in order to eliminate measurement errors resulting from the human factor. The examined person made a given neck movement at the clear command of the researcher. First left side bend, then right side bend, then left head rotation, then right side bend, last head tilt forward. The range of motion measured in the research was expressed in degrees. The examiner carried out the measurements without knowing about the study group (blinding) and did not participate in the analysis of the obtained data.

IV (IV) Myometric measurements of the muscle properties of the shoulder girdle (tension, stiffness and flexibility) of the muscles.

The muscle properties were tested using a Myoton Pro 3 miometer (Myoton, Tallinn, Estonia). The measurement is non-invasive and fast, it takes from 3 to 30 seconds depending on the selected option. In the presented work, the 10 measurement repetition mode was selected, from which the device software calculated the average for each of the three parameters (tension, stiffness and elasticity) and saved it in the device memory. The measurement consisted in placing the measuring tip of the myometer always perpendicular to the skin surface at a strictly defined point before and after the therapy. The researcher moved the device towards the examined tissue until the green light on the body of the device turned on. Such an operation activates the electromagnetic mechanism, which generated mechanical impulses with a constant force deforming the muscle at the measuring point through the moved measuring tip. The meter automatically performed a series of pulses (10), and the researcher held the device steadily in the selected position. The pressure of the tip (punch) is short (10 ms) and of low force (0.40 N), which does not cause a neurological reflex muscle contraction response. The impulse caused mechanical vibrations of the examined muscle, according to which the following parameters were calculated after automatic processing by the accelerometric recording processor:

  • F (frequency) - it determines the muscle tension and is calculated as the maximum frequency from the power of the accelerometric signal spectrum and is expressed as in hertz [Hz].
  • S (stiffness) - is calculated from the formula S-MYO = amax. mprobe / ^ l, where amax is the maximum acceleration of the striking measuring tip [kg], a ^ l is the maximum distance the stylus has moved [m]. This parameter is expressed in [N / m] and determines the force generated by the measuring tip of the myometer needed to deform the tested tissue to a specific depth.
  • D (decrement) - free decrease of vibration calculated from the logarithm:

Patient seated steadily and relaxed in a chair with full body support, hands in lap, looking straight ahead. For all patients, six measurement points were carefully indicated on both sides of upper trapezius muscle, i.e. three points on the left upper trapezius (P1, P2, P3) and three on the right upper trapezius (P4, P5, P6). The three testing points were located on an horizontal line between the cervico-thoracic junction of the spine (C7 / Th1) and the shoulder process of scapula in a distance between these points similar for each patient. Going from medial to lateral side the testing points were as follows: (i) the most medial point as P1 on the left and P4 on the right trapezius, which was distant 3 cm laterally from the cervico-thoracic junction of the spine (C7 / Th1); (ii) the next P2 or P5 point (intermediate one) was distant 2 cm laterally from the P1 or P4; (iii) and the most laterally located the P3 or P6 point was distant 2 cm from the P2 or P5 (on the left or right trapezius, respectively)

Myometric measurements were performed on each patient before and after the first, fourth and seventh treatments and 1 month after the last intervention in accordance with the manufacturer's instructions. The examiner carried out the measurements without knowing about the study group (blinding) and did not participate in the analysis of the obtained data.

IV (V) Assessment of health-related quality of life and pain sensation.

  1. Assessment of health-related quality of life using the WHOQoL-BREF scale In order to compare the health-related quality of life before and after therapy, and 1 month after its completion, the subject completed the WHOQoL-BREF questionnaire. All required licenses for the use of the survey in the described research have been obtained.
  2. Assessment of pain perception using the VAS scale Pain was assessed with the VAS analog pain scale in graphic form. The subjects were assessed on a scale of 1 to 10, immediately after the therapy of the muscles of the neck and shoulder girdle on days 1, 4 and 7. Patients were asked to answer: "How much did you feel pain in your muscles during the treatment?" The VAS scale also determined the intensity of the perceived headache during the last migraine attack before taking part in the treatment cycle and 1 month after the end of treatment by answering the question: "What was the intensity of the last headache / migraine episode?"

V. Statistical analysis. The test results were presented as the arithmetic mean (X) ± standard deviation (SD). The statistical analysis was performed using the STATISTICA v. 10 program (StatSoft, Inc. 2001, Kraków Poland). The Shapiro-Wilk test was used to check the normality of the distribution of serum concentrations of biochemical factors, biomechanical parameters, parameters of muscle properties, myometric tests, tests related to pain and health-related quality of life. Significant deviations from the normal distribution were found, so further analyzes were performed using non-parametric tests. In the case of the analysis of comparisons of several measurements (more than two), the Friedman ANOVA was used and when there were differences between the variables, the Post Hoc For Friedman test. For the comparative analysis of the two measurements (as in the case of the pain analysis), a non-parametric test was used for two dependent samples: Wilcoxon pairwise order. The results were considered statistically significant at the significance level of p <0.05.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Łuć

Study Locations

  • Poland
    • Lubelskie
      • Biała Podlaska, Lubelskie, Poland, 21-500
        • Recruiting
        • Regional Research and Development Center
        • Contact:
          • Aneta Łuć
          • Phone Number: 833428853

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

age: 18 to 65 years of age, female gender, migraine diagnosed by a specialist neurologist for at least 12 months, no metabolic, cardiological, neurological and orthopedic diseases within the shoulder girdle, and cervical spine, voluntary written consent for examination; criteria according to ICHD-3 allowing to classify the symptoms as migraines.

Exclusion Criteria:

minors or over 65 years of age, male gender, patients undergoing pharmacological treatment that cannot be discontinued; people with other headaches; past injuries of the musculoskeletal system in the cervical spine and shoulder girdle; skin diseases and other conditions such as deep vein thrombosis, osteoporosis; criteria for excluding migraine according to ICHD-3.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: chronic migraine (CM)
CM is diagnosed after a patient has experienced a tension or migraine headache for at least 15 days in a month for at least 3 months, when not less than 8 days is characterized by the symptoms typical of migraine diagnosis.
Other: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
Other Names:
  • MTRPs therapy
  • trigger points therapy/compression
Experimental: episodic migraine with aura (EMa)
EMa, known as classical migraine, is characterized by an attack of pain lasting several or tens of minutes, during which the appearance of unilateral visual and sensory symptoms from the central nervous system, usually associated with pain and migraine symptoms.
Other: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
Other Names:
  • MTRPs therapy
  • trigger points therapy/compression
Experimental: episodic migraine without aura (EMb)
EMb is diagnosed after at least 5 attacks per month, characterized by a one-sided, pulsating headache of moderate or severe intensity, which increases with physical activity, sometimes with vomiting, and sensitivity to light and sound. This episode of migraine must last from 4 to 72 hours.
Other: Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)
IC-MTrPs intervention was made first on the right side and then on the left side and this order was the same in each patient. Before starting the therapeutic procedure, the MTrPs localizations were identified by palpation and pinch pressure in patients lying back on the couch. During the procedure, a qualified physiotherapist sat behind the subject's head. The pressure was sustained for about 5 seconds with a 2-3 seconds pause. In each subject, the intervention lasted 15 minutes on the same measurement day in the morning. The subjects underwent cycle of seven IC-MTrPs therapeutic sessions, with 3 days brakes between each session, that lasted in total about a 3-weeks (25 days).
Other Names:
  • MTRPs therapy
  • trigger points therapy/compression

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ROM cervical spine
Time Frame: Before the first treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
Before the first treatment.
ROM cervical spine
Time Frame: After the first treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
After the first treatment.
ROM cervical spine
Time Frame: Before the fourth treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
Before the fourth treatment.
ROM cervical spine
Time Frame: After the fourth treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
After the fourth treatment.
ROM cervical spine
Time Frame: Before the seventh treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
Before the seventh treatment.
ROM cervical spine
Time Frame: After the seventh treatment.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
After the seventh treatment.
ROM cervical spine
Time Frame: Described data was collected for 1 month after the last intervention.
The measuring device allowed to assess the range of movement of the cervical spine with the motor control of the patient in the movement of the lateral to the right bend and left side, right and left rotations and forward bends. The ROM values will be expressed in degrees [°].
Described data was collected for 1 month after the last intervention.
Health-related quality of life
Time Frame: Before the first therapy.
Health-related quality of life will be expressed as points of the WHOQoL-BREF scale [point]. The subject completed the WHOQoL-BREF questionnaire.
Before the first therapy.
Health-related quality of life
Time Frame: After the first therapy.
Health-related quality of life will be expressed as points of the WHOQoL-BREF scale [point]. The subject completed the WHOQoL-BREF questionnaire.
After the first therapy.
Health-related quality of life
Time Frame: 1 month after intervention completion, the subject completed the WHOQoL-BREF questionnaire again.
Health-related quality of life will be expressed as points of the WHOQoL-BREF scale [point]. The subject completed the WHOQoL-BREF questionnaire.
1 month after intervention completion, the subject completed the WHOQoL-BREF questionnaire again.
Muscle pain perception
Time Frame: Day 1
The subjects were assessed on a scale of 1 to 10 (VAS scale), immediately after the therapy of the muscles of the neck and shoulder girdle. Muscle pain perception will be expressed in [cm] as the distance between the two end points (between value 1 and 10) of visual analog scale.
Day 1
Muscle pain perception
Time Frame: Day 4
The subjects were assessed on a scale of 1 to 10 (VAS scale), immediately after the therapy of the muscles of the neck and shoulder girdle. Muscle pain perception will be expressed in [cm] as the distance between the two end points (between value 1 and 10) of visual analog scale.
Day 4
Muscle pain perception
Time Frame: Day 7
The subjects were assessed on a scale of 1 to 10 (VAS scale), immediately after the therapy of the muscles of the neck and shoulder girdle. Muscle pain perception will be expressed in [cm] as the distance between the two end points (between value 1 and 10) of visual analog scale.
Day 7
Headache pain perception
Time Frame: Before the treatment cycle.
The VAS scale also determined the intensity of the perceived headache during the last migraine attack. Headache pain perception will be expressed in [cm] as the distance between the two end points (between value 1 and 10) of visual analog scale (VAS).
Before the treatment cycle.
Headache pain perception
Time Frame: 1 month after the end of treatment.
The VAS scale also determined the intensity of the perceived headache during the last migraine attack. Headache pain perception will be expressed in [cm] as the distance between the two end points (between value 1 and 10) of visual analog scale (VAS).
1 month after the end of treatment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myomentric parameter - Frequency
Time Frame: Before the first treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
Before the first treatment.
Myomentric parameter - Frequency
Time Frame: After the first treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
After the first treatment.
Myomentric parameter - Frequency
Time Frame: Before the fourth treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
Before the fourth treatment.
Myomentric parameter - Frequency
Time Frame: After the fourth treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
After the fourth treatment.
Myomentric parameter - Frequency
Time Frame: Before the seventh treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
Before the seventh treatment.
Myomentric parameter - Frequency
Time Frame: After the seventh treatment.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
After the seventh treatment.
Myomentric parameter - Frequency
Time Frame: 1 month after the last intervention.
Frequency. Myotonometric frequency of natural oscillations (F-MYO) expressed in [Hz].
1 month after the last intervention.
Myomentric parameter - Stiffness
Time Frame: Before the first treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
Before the first treatment.
Myomentric parameter - Stiffness
Time Frame: After the first treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
After the first treatment.
Myomentric parameter - Stiffness
Time Frame: Before the fourth treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
Before the fourth treatment.
Myomentric parameter - Stiffness
Time Frame: After the fourth treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
After the fourth treatment.
Myomentric parameter - Stiffness
Time Frame: Before the seventh treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
Before the seventh treatment.
Myomentric parameter - Stiffness
Time Frame: After the seventh treatment.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
After the seventh treatment.
Myomentric parameter - Stiffness
Time Frame: 1 month after the last intervention.
Stiffness. Myotonometric stiffnes (S-MYO) expressed in [N/m].
1 month after the last intervention.
Myomentric parameter - Decrement
Time Frame: Before the first treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
Before the first treatment.
Myomentric parameter - Decrement
Time Frame: After the first treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
After the first treatment.
Myomentric parameter - Decrement
Time Frame: Before the fourth treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
Before the fourth treatment.
Myomentric parameter - Decrement
Time Frame: After the fourth treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
After the fourth treatment.
Myomentric parameter - Decrement
Time Frame: Before the seventh treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
Before the seventh treatment.
Myomentric parameter - Decrement
Time Frame: After the seventh treatment.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
After the seventh treatment.
Myomentric parameter - Decrement
Time Frame: 1 month after the last intervention.
Decrement. Myotonometric decrement of natural oscillations (D-MYO) expressed in logarithm of damping oscillations [log].
1 month after the last intervention.
Blood parameter - SP
Time Frame: Before the treatment on the first day.
The concentration of substance P was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of substance P expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
Before the treatment on the first day.
Blood parameter - SP
Time Frame: After the treatment on the first day.
The concentration of substance P was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of substance P expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
After the treatment on the first day.
Blood parameter - SP
Time Frame: 24 hours after the sixth treatment.
The concentration of substance P was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of substance P expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
24 hours after the sixth treatment.
Blood parameter S100beta
Time Frame: Before the treatment on the first day.
The concentration of protein S100beta was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of protein S100beta expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
Before the treatment on the first day.
Blood parameter S100beta
Time Frame: After the treatment on the first day.
The concentration of protein S100beta was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of protein S100beta expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
After the treatment on the first day.
Blood parameter S100beta
Time Frame: 24 hours after the sixth treatment.
The concentration of protein S100beta was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of protein S100beta expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
24 hours after the sixth treatment.
Blood parameter CGRP
Time Frame: Before the treatment on the first day.
The concentration of calcitonin gene-related peptide (CGRP) was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of calcitonin gene-related peptide (CGRP) expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
Before the treatment on the first day.
Blood parameter CGRP
Time Frame: After the treatment on the first day.
The concentration of calcitonin gene-related peptide (CGRP) was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of calcitonin gene-related peptide (CGRP) expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
After the treatment on the first day.
Blood parameter CGRP
Time Frame: 24 hours after the sixth treatment.
The concentration of calcitonin gene-related peptide (CGRP) was determined by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of calcitonin gene-related peptide (CGRP) expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
24 hours after the sixth treatment.
Blood parameter BNDF
Time Frame: Before the treatment on the first day.
The concentration of BNDF (brain-derived neurotrophic factor) was determied by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of BNDF expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
Before the treatment on the first day.
Blood parameter BNDF
Time Frame: After the treatment on the first day.
The concentration of BNDF (brain-derived neurotrophic factor) was determied by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of BNDF expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
After the treatment on the first day.
Blood parameter BNDF
Time Frame: 24 hours after the sixth treatment.
The concentration of BNDF (brain-derived neurotrophic factor) was determied by immunochemical ELISA method according to the kit manufacturers' instructions (R&D systems, London UK). The concentration of BNDF expressed in [ng/ml]. Peripheral blood from the ulnar vein was collected on an empty stomach between 6:00 am and 9:00 am into test tubes without serum anticoagulants.
24 hours after the sixth treatment.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Józef Piłsudski University of Physical Education

Collaborators

University School of Physical Education in Wroclaw

Investigators

  • Study Director: Aneta Łuć, Regional Research and Development Center in Biała Podlaska

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2018

Primary Completion (Anticipated)

March 1, 2023

Study Completion (Anticipated)

March 2, 2023

Study Registration Dates

First Submitted

November 23, 2022

First Submitted That Met QC Criteria

December 2, 2022

First Posted (Actual)

December 12, 2022

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SKE 01-52 / 2017
  • 14/21//10/11/2017 (Registry Identifier: Regional Research and Development Center in Biała Podlaska)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Pain

Clinical Trials on Ischemic Compression of Myofascial Trigger Points (IC-MTRPs)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe